Do GLP-1s Raise Your Heart Rate? What the Evidence Shows [2026]

Yes, GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound do raise resting heart rate, and this shows up consistently across large clinical trials. The increase is real but usually small, averaging somewhere between 1 and 4 beats per minute, though a meaningful minority of people see bigger jumps. This guide walks through what the actual evidence says, how strong that evidence is, why it happens, and when a faster heartbeat is worth a call to your doctor.

The Short Version of What the Evidence Shows

The heart rate effect of GLP-1 drugs is one of the better-documented side effects in this drug class. It has been measured in tens of thousands of people across many trials, and the findings line up well from study to study. That consistency is what makes the evidence here strong.

What the data shows, in plain terms:

On average, resting heart rate goes up a few beats per minute.
A subset of people, somewhere around a quarter in some trials, have at least one visit where their heart rate is 20 or more beats above where they started.
Despite this, the same drugs have lowered the rate of heart attacks, strokes, and cardiovascular death in the people studied.

That last point is the part that surprises people. A faster heart rate is generally a risk marker, yet these medications still reduced cardiovascular events overall. We will get into how both things can be true.

How Much Do GLP-1s Raise Heart Rate?

The cleanest way to answer this is to look at the average increase measured against placebo in randomized trials. A 2026 systematic review and meta-analysis pooled the results from trials in people with overweight or obesity who did not have diabetes. Here is what it found for the most common drugs.

Medication	Mean heart rate increase vs. placebo	95% confidence interval
Semaglutide (Ozempic, Wegovy)	+3.35 bpm	1.69 to 5.01
Liraglutide (Saxenda, Victoza)	+2.37 bpm	1.86 to 2.89
Tirzepatide (Mounjaro, Zepbound)	+2.05 bpm	0.96 to 3.13

These are averages, and averages hide the spread. The drug labels and the original trials make the spread clear.

The FDA prescribing information for Wegovy reports a mean resting heart rate increase of 1 to 4 bpm in treated adults compared with placebo. But it also reports something more useful for an individual patient: more people on the drug than on placebo had a maximum change from baseline, at any single visit, of 10 to 19 bpm (41% vs. 34%) and 20 bpm or more (26% vs. 16%). So a quarter of people on Wegovy hit a 20-plus bpm jump at some point during the trial, versus 16% on placebo.

The diabetes trials tell the same story. In SUSTAIN-6, the cardiovascular outcomes trial for semaglutide in type 2 diabetes, the higher dose raised heart rate by roughly 2.8 to 3.2 bpm on average. As in the weight-loss trials, more people on semaglutide than on placebo recorded a maximum single-visit jump of 10 to 19 bpm, and 20 bpm or more, so the average understates what some individuals experienced. In LEADER, the liraglutide outcomes trial, heart rate rose by about 3 bpm (95% CI 2.5 to 3.4), alongside a small drop in systolic blood pressure of about 1.2 mmHg. For tirzepatide, the SURPASS diabetes trials showed dose-dependent increases, with the 5, 10, and 15 mg doses pushing heart rate up by roughly 1 to 4, 2 to 4, and 3 to 6 bpm respectively by the end of treatment.

The pattern worth remembering across all of these trials is the gap between the average and the tail. The average rise is small enough to ignore. The tail, the people who occasionally spike 20-plus bpm above baseline, is large enough that it is worth checking your own numbers rather than assuming you are in the calm middle of the distribution.

Is It Dose-Dependent?

Somewhat, but not dramatically. Tirzepatide showed a clearer dose relationship than semaglutide, with the increase growing as the dose climbed from 5 mg to 15 mg. For semaglutide, the difference between doses is smaller and less consistent. The practical takeaway is that higher doses can mean a slightly faster heart rate, but the effect plateaus and stays modest for most people.

Does It Go Away Over Time?

Mostly no, and this is an honest weak spot in the reassuring narrative. The heart rate bump appears within the first few weeks of treatment and tends to persist for as long as you stay on the drug. It does not usually keep climbing, but it also does not fully reverse while you are taking the medication. When people stop the drug, heart rate generally returns toward baseline. So if you are tracking your own numbers, expect the new, slightly higher resting rate to be your normal while on treatment.

Why Do GLP-1s Speed Up the Heart?

For a long time the mechanism was debated, and the honest answer is that it is still not fully settled. Three explanations have been proposed, and they may all play a part.

Direct action on the heart's pacemaker. This is the explanation with the strongest recent evidence. A 2024 study in pigs, whose heart electrical system closely resembles ours, showed that GLP-1 speeds the sinus node, the heart's natural pacemaker, directly. The effect survived blocking the nerves that normally control heart rate, which means the drug acts on the pacemaker cells themselves rather than working only through the nervous system. The researchers traced it to GLP-1 receptors on pacemaker cells triggering calcium signaling that makes them fire faster.
Shifts in the autonomic nervous system. Some studies suggest GLP-1 drugs dial down vagal (parasympathetic) tone, the "brake" on your heart, or nudge up sympathetic ("gas pedal") activity. This would also raise the resting rate.
A reflex response to other changes. GLP-1 drugs tend to lower blood pressure. A drop in blood pressure can trigger a small reflexive rise in heart rate to keep blood flowing.

The bottom line on mechanism: the direct pacemaker effect now has the best experimental support, but it almost certainly is not the whole story, and the relative weight of each pathway in humans is not nailed down.

Why the Mechanism Matters for You

This is not just academic. If the heart rate rise came purely from a stress-like sympathetic surge, you might expect it to bring the harmful baggage that comes with chronic stress on the heart, like more arrhythmias and higher blood pressure. But that is not what the trials show. Blood pressure tends to fall, not rise, on these drugs, and arrhythmia rates do not climb in the large datasets. A direct, gentle nudge to the pacemaker is more consistent with a faster but otherwise orderly heartbeat than with a heart under strain. That fits the broader picture of a small heart rate increase that travels alongside clear cardiovascular benefit rather than harm.

Does a Faster Heart Rate Mean GLP-1s Are Bad for Your Heart?

This is the question that actually matters, and it is where people get confused. In the general population, a higher resting heart rate is linked to worse cardiovascular outcomes. So a drug that raises heart rate should, in theory, be a concern.

The trial evidence points the other way. The same GLP-1 drugs that raise heart rate have, in large outcomes trials, reduced major cardiovascular events.

Trial	Drug	Population	Key cardiovascular result
SELECT (2023)	Semaglutide 2.4 mg	Overweight/obese, prior CV disease, no diabetes	20% lower risk of CV death, heart attack, or stroke (HR 0.80)
SUSTAIN-6 (2016)	Semaglutide	Type 2 diabetes, high CV risk	26% lower risk of the primary CV composite
LEADER (2016)	Liraglutide	Type 2 diabetes, high CV risk	Lower CV death and all-cause mortality

How can a drug raise heart rate and still cut cardiac events? A few reasons. The heart rate increase is small. The benefits, like weight loss, lower blood pressure, less inflammation, and better blood sugar, appear to outweigh the modest cost of a faster pulse. And the heart rate link to bad outcomes in the general population may not transfer cleanly to a situation where the rate rise is caused by a drug doing many other helpful things at the same time.

It helps to look at how large the cardiovascular benefit actually was. In SELECT, the largest of these trials, semaglutide cut the combined risk of cardiovascular death, nonfatal heart attack, and nonfatal stroke from 8.0% on placebo to 6.5% on the drug over roughly three years, a 20% relative reduction. That benefit appeared in people who did not have diabetes, which means it was not simply a side effect of better blood sugar control. The drug also produced about 10% weight loss and meaningful reductions in waist size. So the trade is a few extra beats per minute in exchange for fewer heart attacks and strokes. For most people at risk, that is a trade worth making.

One honest limitation: trials enroll people who meet entry criteria and are watched closely. They underrepresent people with severe baseline tachycardia or unstable arrhythmias, because those people are often excluded. So the reassuring outcome data are strongest for the broad middle of patients and weaker for the high-risk edges. That is exactly why the next section on who needs closer monitoring matters.

What About Arrhythmias?

A reasonable worry: if the heart beats faster, does it beat more erratically? A large 2022 meta-analysis of 56 randomized trials and nearly 80,000 participants looked specifically at this. The reassuring headline is that GLP-1 drugs did not significantly raise the risk of atrial fibrillation (RR 0.97), atrial flutter (RR 0.83), or sudden cardiac death (RR 0.89).

Two honest caveats sit underneath that headline. Ventricular arrhythmias trended slightly higher without reaching statistical significance overall (RR 1.24), and in subgroup analyses, higher doses and higher baseline BMI were tied to more ventricular arrhythmia signals. Subgroup findings are exploratory and can be driven by chance, so they are a flag for monitoring, not proof of harm. The weight of the evidence is reassuring; it is not a guarantee for every individual.

Who Should Pay Closer Attention

For a healthy adult, a 2 to 4 bpm rise is something you will likely never feel and that carries little consequence. Some people, though, warrant closer monitoring before and during treatment:

People who already have a fast resting heart rate (say, above 85 to 90 bpm).
People with a known arrhythmia like atrial fibrillation, or conditions like POTS.
People with heart failure, particularly heart failure with preserved ejection fraction.
People on other medications or with conditions that also raise heart rate.

If any of these apply, that does not automatically rule out a GLP-1 drug. It means the conversation with your prescriber should include a baseline heart rate check and a plan to recheck it.

How to Monitor and Manage It

The FDA label for Wegovy recommends monitoring heart rate at regular intervals and tells patients to report palpitations or a racing heartbeat at rest. That is sensible practice for any GLP-1 drug. Here is a practical approach.

Situation	What to do
Starting a GLP-1 drug	Check and record your resting heart rate before you begin
First few months	Recheck periodically; a rise of a few bpm is expected
Resting rate stays above 100 bpm	Contact your prescriber; do not just push through it
New palpitations, racing at rest	Report it; may need an EKG to rule out other causes
Chest pain, fainting, severe shortness of breath	Seek urgent care immediately

A few self-management basics help. Stay well hydrated, since dehydration from GLP-1 nausea or reduced intake can raise heart rate on its own. Watch caffeine. And keep a simple log of your morning resting pulse so you and your doctor are working from data, not guesswork. Most increases are manageable with monitoring alone, and stopping the drug fully reverses the effect if it ever becomes a problem.

How to Measure Your Resting Heart Rate Correctly

Bad measurements cause needless worry. To get a number you can trust, take your pulse after sitting quietly for at least five minutes, ideally first thing in the morning before coffee. A wrist or chest-strap monitor works, or you can count beats at your wrist for 30 seconds and double it. Avoid checking right after climbing stairs, after caffeine, or when you are anxious, because all of those temporarily raise the rate and will make a normal drug effect look alarming.

A normal resting heart rate for adults runs roughly 60 to 100 bpm. If your pre-treatment baseline was, say, 70 bpm, then seeing 73 to 74 bpm after starting a GLP-1 drug is right in the expected range and not a cause for concern. A reading that climbs to the high 90s or over 100 and stays there is the kind of sustained change worth flagging. The point of a baseline is to give that judgment a reference, instead of reacting to a single high reading taken at a bad moment.

How GLP-1s Compare to the Alternatives

Heart rate is just one factor. If a faster pulse is a real concern for you, it helps to know how the options stack up. All current GLP-1 and dual-agonist drugs raise heart rate to a broadly similar, modest degree, so switching from semaglutide to tirzepatide is not a reliable way to escape the effect. The differences between them are small and inconsistent across studies.

Older weight-loss drugs are a different story. Stimulant-based options like phentermine raise heart rate and blood pressure through a clearly different and often stronger mechanism, which is why they carry tighter cardiovascular cautions. If anything, the GLP-1 class looks favorable on heart safety compared with that older generation, because the heart rate cost comes bundled with proven cardiovascular benefit.

For people who genuinely cannot tolerate the heart rate effect, the realistic alternatives are non-drug approaches, bariatric surgery in eligible patients, or working with a cardiologist to manage both the rate and the GLP-1 therapy together rather than abandoning a drug that may be protecting the heart in other ways.

Who This Drug Class Is For

GLP-1 medications make sense for most people with obesity or type 2 diabetes who need them, even given the heart rate effect, because the overall cardiovascular ledger runs in their favor. The heart rate rise is small, expected, and manageable.

They call for extra caution, not avoidance, in people with pre-existing tachycardia, certain arrhythmias, or advanced heart conditions. Those people should start with a baseline heart rate, monitor more closely, and stay in contact with both the prescriber and, where relevant, a cardiologist. The decision is rarely "yes or no." It is "yes, with a monitoring plan."

Frequently Asked Questions

How much does Ozempic raise your heart rate?

On average, semaglutide (the drug in Ozempic and Wegovy) raises resting heart rate by about 2 to 4 beats per minute compared with placebo, with pooled trial estimates around 3.35 bpm. Most people never notice it. A minority, though, see larger jumps of 10 to 20 or more bpm at some point during treatment, which is why periodic monitoring is recommended.

Is the heart rate increase from GLP-1 drugs dangerous?

For most healthy adults, no. The increase is small, and the same drugs have reduced heart attacks, strokes, and cardiovascular death in large trials. A 2022 meta-analysis found no significant rise in atrial fibrillation or sudden cardiac death. It becomes a concern mainly for people who already have a fast heart rate, an arrhythmia, or certain heart conditions, and for anyone whose resting rate stays above 100 bpm.

Does the heart rate increase go away over time?

Usually not while you are on the drug. The rise appears within the first few weeks and tends to persist throughout treatment rather than fading. The good news is it does not generally keep climbing, and it returns toward your baseline after you stop the medication.

Should I stop my GLP-1 medication if my heart rate goes up?

Not on your own. A small, expected rise of a few bpm is normal and not a reason to stop. Contact your prescriber if your resting heart rate consistently stays above 100 bpm, if you develop persistent palpitations, or if you have chest pain, fainting, or severe shortness of breath. The decision to continue, adjust the dose, or stop should be made with your doctor.

Does tirzepatide (Mounjaro) raise heart rate more than semaglutide?

Not meaningfully. Both raise resting heart rate by a similar modest amount, with pooled estimates of roughly 2 bpm for tirzepatide and 3 bpm for semaglutide. Tirzepatide shows a clearer dose relationship, so the higher 15 mg dose can push the increase up a bit more. Switching between the two is not a reliable way to avoid the effect.

Sources

This article is for general information and is not medical advice. Talk to a licensed healthcare provider before starting, stopping, or changing any medication.